Alimta(pemetrexed)
Alimta, Armisarte, Ciambra, Pemetrexed, Pemfexy (pemetrexed) is a small molecule pharmaceutical. Pemetrexed was first approved as Alimta on 2004-02-04. It is used to treat mesothelial neoplasms and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat mesothelioma and non-small-cell lung carcinoma. The pharmaceutical is active against dihydrofolate reductase. In addition, it is known to target proton-coupled folate transporter, thymidylate synthase, and trifunctional purine biosynthetic protein adenosine-3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Alimta, Pemfexy (generic drugs available since 2022-05-25)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pemetrexed
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PEMETREXED | Allergan | N-208419 RX | 2020-08-21 | 3 products, RLD, RS |
| PEMFEXY | Eagle Pharmaceuticals | N-209472 RX | 2020-02-08 | 1 products, RLD, RS |
Pemetrexed disodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PEMETREXED DISODIUM | ACCORD HLTHCARE | N-214408 RX | 2022-07-19 | 4 products, RLD, RS |
| PEMETREXED DISODIUM | Hospira | N-214218 RX | 2022-06-22 | 3 products, RLD, RS |
| ALIMTA | Eli Lilly | N-021462 RX | 2004-02-04 | 2 products, RLD, RS |
| PEMETREXED DISODIUM | Sandoz | N-214657 RX | 2022-05-26 | 3 products, RLD, RS |
| PEMETREXED | Shilpa Medicare | N-215179 RX | 2023-05-22 | 3 products, RLD, RS |
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mesothelial neoplasms | — | D018301 | — |
| non-small-cell lung carcinoma | — | D002289 | — |
Agency Specific
FDA
EMA
No data
Clinical
Clinical Trials
1190 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 126 | 368 | 174 | 16 | 36 | 659 |
| Mesothelioma | D008654 | — | C45 | 12 | 21 | 7 | 3 | 1 | 36 |
| Adenocarcinoma of lung | D000077192 | — | — | 5 | 20 | 2 | 2 | 5 | 32 |
| Adenocarcinoma | D000230 | — | — | 4 | 8 | 3 | 2 | — | 15 |
| Thymoma | D013945 | — | — | 1 | 1 | — | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 29 | 99 | 22 | — | 8 | 142 |
| Neoplasms | D009369 | — | C80 | 72 | 30 | 11 | — | — | 97 |
| Malignant mesothelioma | D000086002 | — | — | 18 | 29 | 5 | — | 5 | 48 |
| Head and neck neoplasms | D006258 | — | — | 7 | 11 | 2 | — | — | 18 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 9 | 10 | 1 | — | — | 17 |
| Small cell lung carcinoma | D055752 | — | — | 6 | 7 | 3 | — | — | 15 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 9 | 1 | — | — | 11 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 4 | 1 | — | — | 9 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 4 | 2 | — | 1 | 9 |
| Carcinoma | D002277 | — | C80.0 | 3 | 3 | 3 | — | — | 8 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 17 | — | — | — | 22 |
| Colorectal neoplasms | D015179 | — | — | 10 | 16 | — | — | — | 20 |
| Urologic neoplasms | D014571 | — | C64-C68 | 4 | 8 | — | — | — | 10 |
| Melanoma | D008545 | — | — | 5 | 5 | — | — | — | 7 |
| Sarcoma | D012509 | — | — | 2 | 5 | — | — | — | 7 |
| Peritoneal neoplasms | D010534 | — | — | 2 | 4 | — | — | — | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 3 | — | — | 1 | 6 |
| Immunotherapy | D007167 | — | — | — | 3 | — | — | 2 | 5 |
| Fallopian tube neoplasms | D005185 | — | — | 3 | 2 | — | — | — | 5 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 3 | — | — | — | 5 |
Show 53 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uveal neoplasms | D014604 | EFO_1001230 | — | 2 | — | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 2 | — | — | — | — | 2 |
| Chordoma | D002817 | EFO_0000334 | — | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Chondrosarcoma | D002813 | — | — | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Medical sociology | D012962 | — | — | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 1 | 1 |
| Pulpitis | D011671 | EFO_1001139 | K04.0 | — | — | — | — | 1 | 1 |
| Lasers | D007834 | — | — | — | — | — | — | 1 | 1 |
| Periapical periodontitis | D010485 | EFO_1001391 | K04.5 | — | — | — | — | 1 | 1 |
| Nonvital tooth | D019553 | — | — | — | — | — | — | 1 | 1 |
| Circulating neoplastic cells | D009360 | — | — | — | — | — | — | 1 | 1 |
| Neutropenia | D009503 | — | D70 | — | — | — | — | 1 | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | — | 1 | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | — | 1 | 1 |
| Sensitivity and specificity | D012680 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pemetrexed |
| INN | pemetrexed |
| Description | Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..
|
| Classification | Small molecule |
| Drug class | antineoplastic thymidylate synthetase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 137281-23-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL225072 |
| ChEBI ID | 63616 |
| PubChem CID | 446556 |
| DrugBank | DB00642 |
| UNII ID | 04Q9AIZ7NO (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pemfexy – Eagle Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Alimta – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 21,493 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,527 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use